Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

23 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Xeljanz Articles

EMA committee gives thumbs down for Pfizer's Xeljanz for RA

26 April 2013

BioTrends views Xeljanz and Zytiga prescribing in USA

26 March 2013

Regulatory briefs on Bayer's Stivarga, Boehringer/Lilly's empagliflozin and Pfizer's Xeljanz

26 March 2013

US Senator calls for re-examination of pricing of drugs developed with public funds

20 March 2013

Newly approved tofacitinib slows rheumatoid arthritis joint damage

24 January 2013

FDA approves Pfizer's Xeljanz for rheumatoid arthritis

7 November 2012

Showing 1-6 of 6 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
  • Pfizer to split-off remaining 80% interest in Zoetis
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
  • Pfizer to split-off remaining 80% interest in Zoetis

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS